Phase I study on patients with oxi refractory/intolerant KRAS mutant CRC
coloCan
CSN Member Posts: 1,944 Member
announced this date by Calgary, Canada-based Oncolytics Biotech, which will consist of FOLFIRI (Leucovorin,5FU and Irinotecan)with this new thing called Reolysin (REO). For more info see www.prnewsire.com or
rttnews.com
Hope this helps someone
rttnews.com
Hope this helps someone
0
Discussion Boards
- All Discussion Boards
- 6 CSN Information
- 6 Welcome to CSN
- 122.5K Cancer specific
- 2.8K Anal Cancer
- 455 Bladder Cancer
- 311 Bone Cancers
- 1.6K Brain Cancer
- 28.6K Breast Cancer
- 406 Childhood Cancers
- 27.9K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.2K Gynecological Cancers (other than ovarian and uterine)
- 13K Head and Neck Cancer
- 6.4K Kidney Cancer
- 681 Leukemia
- 802 Liver Cancer
- 4.2K Lung Cancer
- 5.1K Lymphoma (Hodgkin and Non-Hodgkin)
- 242 Multiple Myeloma
- 7.2K Ovarian Cancer
- 69 Pancreatic Cancer
- 493 Peritoneal Cancer
- 5.6K Prostate Cancer
- 1.2K Rare and Other Cancers
- 544 Sarcoma
- 743 Skin Cancer
- 659 Stomach Cancer
- 192 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.9K Uterine/Endometrial Cancer
- 6.4K Lifestyle Discussion Boards